GlaxoSmithKline's immunology leader Nucala has been locked in a yearslong struggle with AstraZeneca's Fasenra for dominance in rare eosinophilic asthma. With a new rare disease approval, Nucala just ...

GlaxoSmithKline’s Nucala needs a win in its fight against AstraZeneca’s Fasenra. Now, it can at least tout a first-data advantage in a rare inflammatory disease. In a phase 3 study, the rate of ...

Third US indication for Nucala demonstrates GSK’s commitment to finding new ways to help patients with eosinophil-driven diseases Dr Hal Barron, Chief Scientific Officer and President R&D, GSK, said: ...

GSK now has the global development and commercialisation rights to the COPD-targeting oligonucleotide, EMP-012.

Yesterday, GSK added a new antibody-drug conjugate to its cancer pipeline via a $358 million agreement with French biotech ...

Previously, the treatment had only been available as a lyophilized powder for reconstitution that required administration by a healthcare professional. The Food and Drug Administration has approved ...

The approval was based on data from the phase 3 SYNAPSE study that evaluated mepolizumab as an add-on maintenance treatment in over 400 adults with CRSwNP. The Food and Drug Administration (FDA) has ...

(Reuters) -British drugmaker GSK said on Friday that its asthma drug, Nucala, met the main goal of a late-stage study in treating patients with chronic obstructive pulmonary disease (COPD), or ...

Nucala (100mg dose subcutaneous injection) was first approved in 2015 as an add-on maintenance treatment for patients with severe eosinophilic asthma aged 12 years and older. This approval (40mg dose ...

LONDON, March 6, 2017 /PRNewswire/ -- GlaxoSmithKline plc (LSE/NYSE:GSK) today announced data demonstrating that severe asthma patients, whose disease is driven by eosinophilic inflammation, treated ...